Drug Trial Radar · NCT02131220
Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction
Last checked: Nov 20, 2026Latest source record: Aug 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
362
Actual
Start
Nov 2015
Primary completion
Aug 2017
Study completion Sep 2017
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 6, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether intracoronary selective thrombolysis are more effective than tirofiban on the coronary flow during primary percutaneous coronary intervention for the acute myocardial infarction.
Conditions
- Myocardial Infarction
- Percutaneous Coronary Intervention
- Thrombolytic Therapy
Interventions
ProurokinaseDrug
20mg intracoronary bolus infusion using selective catheter during PCI
TirofibanDrug
10ug/kg intracoronary bolus infusion using selective catheter during PCI
normal salineDrug
intracoronary bolus infusion using selective catheter during PCI
Primary outcomes
What the sponsor says the trial is designed to measure.
- Coronary flow using corrected Thrombolysis In Myocardial Infarction Frame Count (cTFC)Time frame: At the end of Percutaneous Coronary Intervention procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Cardiology, Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.